NASDAQ · GLSI
Healthcare · Biotechnology
$16.67
Up+$1.36 (+8.88%)
Updated Aug 22, 2026, 9:03 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GLSI closed at $16.67 after 21 trading sessions, up 28.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $16.16 | $17.48 | $15.5401 | $16.67 | 176.79K |
| Aug 20, 2026 | $17.41 | $17.68 | $15.00 | $15.31 | 181.62K |
| Aug 19, 2026 | $17.70 | $18.17 | $17.17 | $17.34 | 112.13K |
| Aug 18, 2026 | $17.06 | $17.85 | $16.90 | $17.26 | 102.51K |
| Aug 17, 2026 | $16.80 | $17.75 | $16.55 | $17.38 | 92.65K |
| Aug 14, 2026 | $16.475 | $17.42 | $15.96 | $16.80 | 116.52K |
| Aug 13, 2026 | $17.06 | $17.1199 | $16.2752 | $16.38 | 77.01K |
| Aug 12, 2026 | $15.85 | $17.74 | $15.60 | $16.92 | 200.44K |
| Aug 11, 2026 | $15.87 | $16.14 | $14.80 | $15.55 | 107.31K |
| Aug 10, 2026 | $14.79 | $16.225 | $14.76 | $15.50 | 176.18K |
| Aug 7, 2026 | $14.52 | $14.745 | $14.20 | $14.36 | 88.49K |
| Aug 6, 2026 | $14.31 | $14.97 | $14.24 | $14.24 | 87.62K |
| Aug 5, 2026 | $14.39 | $14.75 | $14.1889 | $14.39 | 81.44K |
| Aug 4, 2026 | $13.53 | $14.57 | $13.1901 | $14.35 | 151.08K |
| Aug 3, 2026 | $13.46 | $14.17 | $13.18 | $13.54 | 123.31K |
| Jul 31, 2026 | $14.21 | $14.30 | $13.24 | $13.50 | 85.72K |
| Jul 30, 2026 | $12.97 | $14.3537 | $12.97 | $14.02 | 116.98K |
| Jul 29, 2026 | $13.59 | $14.09 | $12.59 | $12.80 | 102.93K |
| Jul 28, 2026 | $13.32 | $13.75 | $12.90 | $13.45 | 161.87K |
| Jul 27, 2026 | $13.54 | $14.08 | $13.15 | $13.44 | 133.07K |
| Jul 24, 2026 | $13.18 | $13.50 | $12.51 | $12.98 | 113.81K |
The latest Smart Investors Daily articles mentioning GLSI.
GLSI research
Company profile and research snapshot.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 30, 2026
STAFFORD, Texas, April 30, 2026 -- Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track...
Benzinga · Mar 19, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga · Mar 18, 2026
Benzinga · Mar 17, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLSI.
